Targeted delivery of drugs to treat resistant brain tumors
Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma
This study is exploring a new way to deliver medicine directly to glioblastoma tumors to make treatments work better, and it’s for patients who are dealing with this tough type of brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-10997330 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver drugs specifically to glioblastoma tumors, which are known for being resistant to standard treatments. The approach involves using a specialized liposomal formulation that combines a novel drug with existing therapies to enhance their effectiveness. By targeting the tumor more effectively, the goal is to improve patient outcomes and survival rates. The research also investigates the role of a specific protein, Neuroplin-1, in the resistance of these tumors to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have shown resistance to standard therapies like Temozolomide.
Not a fit: Patients with glioblastoma who are not resistant to current therapies or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with targeted drug delivery methods in similar contexts, indicating potential for success in this novel approach.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Quinones-Hinojosa, Alfredo — Mayo Clinic Jacksonville
- Study coordinator: Quinones-Hinojosa, Alfredo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.